Needham Reiterates Buy on Revance Therapeutics, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Revance Therapeutics (NASDAQ:RVNC) and maintained a $40 price target.
August 14, 2023 | 3:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Revance Therapeutics has received a reiterated 'Buy' rating from Needham analyst Serge Belanger, with a maintained price target of $40.
The reiterated 'Buy' rating and maintained price target by Needham analyst Serge Belanger indicates a positive outlook for Revance Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100